Table 1 Comparison between CD10 − MUM1... | American Society of Hematology

Table 1

Comparison between CD10⁻MUM1⁺ and CD10⁺MUM1⁻ follicular lymphomas

Features	CD10⁻MUM1⁺ FL	CD10⁺MUM1⁻ FL	P
Pathological features
All patients, n	22	119
Grade 3A/B, %	91 (20/22)	17 (20/119)	< .001*
With diffuse area, %	59 (13/22)	19 (23/119)	< .001*
Bcl2 expression, %	59 (13/22)	93.7 (112/119)	< .001*
Bcl6 expression, %	54 (12/22)	72 (86/119)	.1*
BCL2 translocation, %	5 (1/20)	92.5 (110/119)	< .001*
BCL6 translocation, %	30 (6/20)†	4.2 (5/119)	< .001*
BCL6 amplification, %	62 (10/16)†	26 (6/23)‡	< .05*
Only patients of grade 3A/B, n	20	20 + 23‡
With diffuse area, %	55 (11/20)	45 (9/20)	.44*
Bcl2 expression, %	60 (12/20)	80 (16/20)	.17*
Bcl6 expression, %	52 (11/21)	70 (14/20)	.24*
BCL2 translocation, %	5.3 (1/19)	60 (12/20)	< .001*
BCL6 translocation, %	32 (6/19)†	16 (7/43)‡	.17*
BCL6 amplification, %	62 (10/16)†	26 (6/23)‡	< .05*
Clinical features
All patients, n	22	129
Sex, no. male:female	16:6	53:66	< .01*
Age, y	67.0	58.7	< .001§
B symptoms, no. +:−	5:12	16:88	.16*
No. stage I + II:III + IV	12:10	57:57	.70*
LDH level, U/I	423	428	.44§
Only patients of grade 3A/B, n	20	25
Sex, no. male:female	15:5	16:9	.43*
Age, y	65.3	57.4	< .01§
B symptoms, no. +:−	5:12	6:13	.94*
No. stage I + II:III + IV	10:10	13:8	.44*
LDH level, U/I	496	740	.41§

Features	CD10⁻MUM1⁺ FL	CD10⁺MUM1⁻ FL	P
Pathological features
All patients, n	22	119
Grade 3A/B, %	91 (20/22)	17 (20/119)	< .001*
With diffuse area, %	59 (13/22)	19 (23/119)	< .001*
Bcl2 expression, %	59 (13/22)	93.7 (112/119)	< .001*
Bcl6 expression, %	54 (12/22)	72 (86/119)	.1*
BCL2 translocation, %	5 (1/20)	92.5 (110/119)	< .001*
BCL6 translocation, %	30 (6/20)†	4.2 (5/119)	< .001*
BCL6 amplification, %	62 (10/16)†	26 (6/23)‡	< .05*
Only patients of grade 3A/B, n	20	20 + 23‡
With diffuse area, %	55 (11/20)	45 (9/20)	.44*
Bcl2 expression, %	60 (12/20)	80 (16/20)	.17*
Bcl6 expression, %	52 (11/21)	70 (14/20)	.24*
BCL2 translocation, %	5.3 (1/19)	60 (12/20)	< .001*
BCL6 translocation, %	32 (6/19)†	16 (7/43)‡	.17*
BCL6 amplification, %	62 (10/16)†	26 (6/23)‡	< .05*
Clinical features
All patients, n	22	129
Sex, no. male:female	16:6	53:66	< .01*
Age, y	67.0	58.7	< .001§
B symptoms, no. +:−	5:12	16:88	.16*
No. stage I + II:III + IV	12:10	57:57	.70*
LDH level, U/I	423	428	.44§
Only patients of grade 3A/B, n	20	25
Sex, no. male:female	15:5	16:9	.43*
Age, y	65.3	57.4	< .01§
B symptoms, no. +:−	5:12	6:13	.94*
No. stage I + II:III + IV	10:10	13:8	.44*
LDH level, U/I	496	740	.41§

Values in parentheses indicate no. of patients out of the total evaluable.

χ² test.

One patient showed both BCL6 gene translocation and amplification.

Twenty-three patients of CD10⁺MUM1⁻FL (grade 3) were added to previous patients for analysis of BCL6 gene abnormality.

t test.